Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Ruzsa A, Sen M, Evans M, Lee LW, Hideghety K, Rottey S, Klimak P, Holeckova P, Fayette J, Csoszi T, Erfan J, Forssmann U, Goddemeier T, Bexon A, Nutting C; NA EMD 1201081 Study Group.

Invest New Drugs. 2014 Dec;32(6):1278-84. doi: 10.1007/s10637-014-0117-2. Epub 2014 Jun 4.

PMID:
24894651
2.

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Machiels JP, Kaminsky MC, Keller U, Brümmendorf TH, Goddemeier T, Forssmann U, Delord JP.

Invest New Drugs. 2013 Oct;31(5):1207-16. doi: 10.1007/s10637-013-9933-z. Epub 2013 Feb 10.

PMID:
23397499
3.

Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt WE, de Marinis F, Heeger S, Goddemeier T, O'Byrne KJ, Gatzemeier U.

Lung Cancer. 2012 Aug;77(2):376-82. doi: 10.1016/j.lungcan.2012.03.010. Epub 2012 Apr 11.

PMID:
22498112
4.

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.

Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O'Byrne KJ, Pirker R.

Lancet Oncol. 2011 Jan;12(1):30-7. doi: 10.1016/S1470-2045(10)70278-3. Epub 2010 Dec 17.

PMID:
21169060
5.

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team.

Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.

PMID:
19410716
6.

Simple-to-use, reference criteria for revealing drug-induced QT interval prolongation in conscious dogs.

Schmitt MW, Von Landenberg F, Poth H, Wimmer E, Goddemeier T, Cavero I.

Eur J Pharmacol. 2007 Jan 5;554(1):46-52. Epub 2006 Oct 10.

PMID:
17112506
7.

Height growth of adolescent German boys and girls.

Wember T, Goddemeier T, Manz F.

Ann Hum Biol. 1992 Jul-Aug;19(4):361-9.

PMID:
1616291
8.

[Breast feeding studies 1981-1983 in 1,500 mothers in Dortmund and Haltern. III. Rates of breast feeding and duration of breast feeding in the first half year].

Kersting M, Wember T, Goddemeier T, Koester H, Wennemann J, Schöch G.

Monatsschr Kinderheilkd. 1987 Jun;135(6):314-9. German.

PMID:
3497340

Supplemental Content

Loading ...
Support Center